TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28466022
Drug: Out-of-plane injection
Normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Out-of-plane injection
Study: 27004917
Drug: Fibrinogen 3g
Normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinogen 3g infusion
Study: 19712040
Drug: Whole-virus H5N1
Normalized name: INFLUENZA A VIRUS H5N1 WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-virus H5N1 clade 1 A/Vietnam vaccine (2-dose priming regimen)
Study: 19712040
Drug: 7.5-microg dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5-microg dose of a clade 2.1 A/Indonesia vaccine (booster)
Study: 17513402
Drug: Gamma-linolenate (GLA)
Normalized name: gamma-linolenate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma-linolenate (GLA) 890 mg/d (5 g/d borage oil)
Study: 17513402
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil (5 g/d)
Study: 14701773
Drug: PS‐341 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PS‐341 1.5 mg/m(2) administered intravenously twice weekly for 2 weeks every 21 days, with dose escalation to 1.7 mg/m(2) in absence of grade 3 to 4 toxicities.
Study: 9441058
Drug: 6-month short-course
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month short-course chemotherapy regimen (SCC) with rifampicin, isoniazid and pyrazinamide for 2 months followed by rifampicin with isoniazid for another 4 months (6R series)
Study: 7951290
Drug: Contract-relax treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contract-relax treatment
Study: 7951290
Drug: Leg pull
Normalized name: Crab leg
DrugBank: Crab leg (DB11011)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leg pull treatment
Study: 3108930
Drug: L-deprenyl 10
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-deprenyl 10 mg/day
Study: 3108930
Drug: L-deprenyl 40
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-deprenyl 40 mg/day
Study: 29966958
Drug: Supplemental heat
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supplemental heat wrap therapy
Study: 29966958
Drug: Multimodal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal treatment without supplemental heat wrap therapy
Study: 27052212
Drug: Clinical medication
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical medication review followed by a pharmaceutical care plan
Study: 19387398
Drug: Thermogenic nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermogenic nutritional supplement
Study: 22088165
Drug: In-home interdisciplinary
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In-home interdisciplinary care management intervention combining palliative care and geriatric medicine approaches.
Study: 17629089
Drug: lafutidine 10
Normalized name: lafutidine
DrugBank: Lafutidine (DB12770)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lafutidine 10 mg
Study: 26201312
Drug: LPZ 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPZ 30 mg
Study: 11383262
Drug: Occlusal adjustment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occlusal adjustment therapy
Study: 11383262
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of splint and occlusal adjustment therapy
Study: 7816382
Drug: Dipyridamole infusion
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dipyridamole infusion
Study: 3862151
Drug: Amphetamine 30
Normalized name: dextroamphetamine 30 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amphetamine 30 mg, p.o.
Study: 26036190
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) with aspirin
Study: 26323997
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa 60 μg/week
Study: 26323997
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa 120 μg/week
Study: 26323997
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa 240 μg/week
Study: 23922479
Drug: Continuous sedation
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous sedation (group Cc)
Study: 18771838
Drug: One-visit root
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-visit root canal treatment
Study: 23792399
Drug: Two-visit root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-visit root canal treatment
Study: 16303215
Drug: Single nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single nasal dose of vaccine containing 15, 30, or 45 microg of each of the three HA antigens
Study: 16303215
Drug: Two nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two nasal doses containing 30 microg of each HA, separated by 2 weeks
Study: 16303215
Drug: Vaccine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine (all doses)
Study: 10957689
Drug: Comprehensive hypertension
Normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive hypertension care program; details on dosage and duration not available.
Study: 8836865
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg alternate day oral aspirin (regular formulation)
Study: 8836865
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg alternate day oral aspirin (enteric coated formulation)
Study: 1445490
Drug: Probucol (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol (250 mg/day)
Study: 3918688
Drug: Omeprazole 10
Normalized name: omeprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 10 mg daily (in smokers)
Study: 3918688
Drug: Omeprazole 30
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole 30 mg daily (in smokers)
Study: 24548425
Drug: Subcutaneous rFeIFN‐ω
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous rFeIFN‐ω (Virbagen® omega, Virbac, Carros, France) administered via eight injections over four months.
Study: 24548425
Drug: Oral rFeIFN‐ω
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rFeIFN‐ω administered daily.
Study: 24548425
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (subcutaneous rFeIFN‐ω).
Study: 21436164
Drug: Ibandronate (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate (3 mg intravenous single dose)
Study: 19473824
Drug: CHO-Meal (control-meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO-Meal (control-meal plus 45 g carbohydrates)
Study: 19473824
Drug: PRO-Meal (control-meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRO-Meal (control-meal plus 45 g of casein)
Study: 19473824
Drug: CHO+PRO-Meal (PRO-meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO+PRO-Meal (PRO-meal plus 45 g carbohydrates)
Study: 19473824
Drug: CHO-Meal (control-meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO-Meal (control-meal plus 45 g carbohydrates) with casein added
Study: 19473824
Drug: PRO+CHO-Meal (PRO-meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRO+CHO-Meal (PRO-meal plus 45 g carbohydrates)
Study: 15572275
Drug: Risperidone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (0.5 mg)
Study: 12233993
Drug: Cocaine-dependent outpatients
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine-dependent outpatients (treatment group)
Study: 29987329
Drug: CGRP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CGRP infusion
Study: 1524277
Drug: Terfenadine 120
Normalized name: terfenadine 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine 120 mg single dose
Study: 1524277
Drug: Terfenadine 60
Normalized name: terfenadine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine 60 mg single dose
Study: 1524277
Drug: Terfenadine 120
Normalized name: terfenadine 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine 120 mg b.i.d. at steady state
Study: 3932106
Drug: Terfenadine 60
Normalized name: terfenadine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine 60 mg b.i.d.
Study: 6350072
Drug: Tioconazole base
Normalized name: Tioconazole
DrugBank: Tioconazole (DB01007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tioconazole base 1% cream applied twice daily
Study: 6350072
Drug: Econazole nitrate
Normalized name: Econazole Nitrate
DrugBank: Econazole (DB01127)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Econazole nitrate 1% cream applied twice daily
Study: 24384865
Drug: Rehydration with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehydration with oral rehydration solution (ORS), average consumption of 2040 mL (range; 1800-2500 mL)
Study: 22375612
Drug: Exenatide twice
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide twice daily plus sitagliptin and metformin (ADD group)
Study: 22375612
Drug: Exenatide twice
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide twice daily plus placebo and metformin (SWITCH group)
Study: 10435066
Drug: Oestradiol therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestradiol therapy (2 mg/day)
Study: 21411832
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg caffeine
Study: 2182444
Drug: Intermediate-dose i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate-dose i.v. methotrexate (ID-MTX) (4 x 0.5 g/m2)
Study: 26588236
Drug: Pazopanib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 800 mg/d
Study: 31601514
Drug: Sunitinib 50
Normalized name: sunitinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 50 mg/d, 4 weeks on/2 weeks off
Study: 31601514
Drug: Pazopanib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 800 mg/d without AE-related dose reductions
Study: 31601514
Drug: Pazopanib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 800 mg/d with AE-related dose reductions
Study: 31601514
Drug: Sunitinib 50
Normalized name: sunitinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 50 mg/d without AE-related dose reductions
Study: 31601514
Drug: Sunitinib 50
Normalized name: sunitinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 50 mg/d with AE-related dose reductions
Study: 28935273
Drug: Etirinotecan pegol
Normalized name: Etirinotecan pegol
DrugBank: Etirinotecan pegol (DB14951)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etirinotecan pegol (EP) administered every 21 days (q21d)
Study: 19543499
Drug: Rush immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rush immunotherapy (RIT) with Dermatophagoides farinae (Der f) and Dermatophagoides pteronyssinus (Der p)
Study: 17292595
Drug: TJ‐114 (Saireito)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TJ‐114 (Saireito) at a dose of 9 g/day for 2 days before surgery and for 2 weeks after surgery
Study: 9742275
Drug: d,l-methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: d,l-methadone
Study: 9742275
Drug: l-methadone
Normalized name: dl-Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: l-methadone
Study: 29944651
Drug: Single-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose oral ciprofloxacin for household contacts within 24 hours of case notification
Study: 26020438
Drug: Low-radiation-dose CT
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-radiation-dose CT images scored by eight radiologists using morphologic categories proposed by the Fleischner Society guidelines.
Study: 19170143
Drug: C. colocynthis
Approvals — FDA: no, EMA: no, PMDA: no
Description: C. colocynthis fruit capsules (100 mg, three times a day)
Study: 11866264
Drug: Anti-H. pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-H. pylori therapy
Study: 10705200
Drug: Combined androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined androgen blockade (CAB) with goserelin acetate 3.6 mg and flutamide 250 mg three times daily
Study: 10705200
Drug: Goserelin acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goserelin acetate 3.6 mg alone
Study: 3530176
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (VCR, NMM, Act.‐D)
Study: 3530176
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (VCR, NMM, Act.‐D, DTIC)
Study: 3530176
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (VCR, Act.‐D, CCNU, DTIC)
Study: 3530176
Drug: DTIC-monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTIC-monotherapy
Study: 3530176
Drug: Cross over
Normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cross over treatment after progression
Study: 24170750
Drug: Baseline medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline medication adherence
Study: 20200301
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir twice daily
Study: 19337555
Drug: CLAs 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLAs 2.5 g (2 g mixture of cis 9‐trans 11 and trans 10‐cis12 CLAs)
Study: 20374312
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E 400 mg
Study: 19337555
Drug: CLAs and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLAs and vitamin E at above doses
Study: 12218524
Drug: Clomethiazole edisilate
Normalized name: Clomethiazole edisilate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomethiazole edisilate (0.8%), 225 ml loading dose followed by 100 ml/h maintenance during surgery
Study: 10334431
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg i.v. verapamil
Study: 24794816
Drug: Nicotinamide treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide treatment
Study: 1957127
Drug: Interferon alpha-2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alpha-2b treatment (3 million units thrice weekly)
Study: 1957127
Drug: Interferon alpha-2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alpha-2b treatment (6 million units thrice weekly for at least 8 weeks)
Study: 7011348
Drug: Tiamenidine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiamenidine (3 mg daily)
Study: 7011348
Drug: Clonidine (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (450 micrograms daily)
Study: 25414152
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment for mild GDM (Control)
Study: 23661035
Drug: Expectations regarding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expectations regarding treatment
Study: 23661035
Drug: Past experience
Normalized name: ALCOHOL 80 mL in 100 mL TOPICAL GEL [Quality Metalcraft Experi-Metal Alcohol Antiseptic 80% Topical Solution Hand Sanitizer Non-sterile Solution]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Past experience with treatment
Study: 18989348
Drug: Ruboxistaurin 32
Normalized name: RUBOXISTAURIN
DrugBank: Ruboxistaurin (DB11829)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruboxistaurin 32 mg/day
Study: 17972425
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (ACE‐I + BB + ARA or ARB)
Study: 17972425
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy (ACE‐I + BB + ARA + ARB)
Study: 17972425
Drug: ACE‐I and
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE‐I and BB combined with diuretics and often with digoxin
Study: 12530553
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (3.5 g EPA and 2.4 g DHA per day, each as the ethyl ester)
Study: 12530553
Drug: Evening primrose
Normalized name: EVENING PRIMROSE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening primrose oil capsules (no detectable EPA or DHA)
Study: 28684614
Drug: Qred (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qred (200 mg/d)
Study: 14585635
Drug: Pulsed-dye laser
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed-dye laser (PDL) treatment
Study: 23137063
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) treatment
Study: 21523262
Drug: WPC preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: WPC preparation
Study: 19257821
Drug: Risedronate (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate (15 mg once per week for patients <40 kg; 30 mg once per week for patients >40 kg)
Study: 17101701
Drug: Removable appliance
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Removable appliance with a palatal crib associated with high-pull chin cup therapy for 12 months
Study: 7656523
Drug: Glucagon (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucagon (1 mg)
Study: 11315834
Drug: Epinephrine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine (0.3 mg)
Study: 9223026
Drug: NaHCO3 (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaHCO3 (250 mg (3 mmol).(kg body weight)‐1)
Study: 8192551
Drug: L-365,260 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-365,260 (50 mg)
Study: 8192551
Drug: L-365,260 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-365,260 (10 mg)
Study: 3359905
Drug: vodka (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: vodka (37.5 ml) in tomato juice
Study: 28179454
Drug: pembrolizumab 10
Normalized name: pembrolizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: pembrolizumab 10 mg/kg i.v. every 2 or 3 weeks until disease progression
Study: 28179454
Drug: pembrolizumab 2
Normalized name: pembrolizumab 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: pembrolizumab 2 or 10 mg/kg i.v. every 3 weeks
Study: 28179454
Drug: ipilimumab 3
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ipilimumab 3 mg/kg every 3 weeks for up to four doses
Study: 28179454
Drug: investigator's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: investigator's choice of chemotherapy
Study: 17221013
Drug: Intravenous dipyrone
Normalized name: dipyrone
DrugBank: Metamizole (DB04817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dipyrone
Study: 23494213
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral treatment program
Study: 18065809
Drug: Atorvastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (80 mg single dose)
Study: 17359691
Drug: Non-reducing group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-reducing group (general pre-operation routine preparation)
Study: 10971238
Drug: Propofol alone
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol alone (n=120, group A, loading dose 40-60 mg IV, followed by repeated doses of 20 mg)
Study: 10971238
Drug: Propofol plus
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol plus midazolam (n=119, group B, initial midazolam dose of 2.5-3.5 mg IV, followed by repeated doses of 20 mg of propofol)
Study: 1310922
Drug: L-(−)-Ephedrine hydrochloride
Normalized name: L-Ephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-(−)-Ephedrine hydrochloride (50 mg three times a day)
Study: 26672637
Drug: Somavaratan 1.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somavaratan 1.15 mg/kg weekly
Study: 26672637
Drug: Somavaratan 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somavaratan 2.5 mg/kg twice monthly
Study: 26672637
Drug: Somavaratan 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somavaratan 5.0 mg/kg monthly
Study: 22497929
Drug: Prehospital stroke
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prehospital stroke treatment in a mobile stroke unit (MSU)
Study: 22497929
Drug: Optimised conventional
Normalized name: Optimised human arginase I
DrugBank: Pegzilarginase (DB14780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimised conventional hospital-based stroke treatment (control group)
Study: 9041371
Drug: Pancreatic clamping
Normalized name: Pancreatin
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancreatic clamping with constant insulin levels
Study: 8105678
Drug: 3-day treatment
Normalized name: Gyne-Lotrimin 2% 3-Day Treatment Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day treatment with amoxicillin and clavulanate potassium (20 mg/kg per day of amoxicillin and 5 mg/kg per day of clavulanate potassium in three divided doses)
Study: 8105678
Drug: 10-day treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day treatment with amoxicillin and clavulanate potassium (20 mg/kg per day of amoxicillin and 5 mg/kg per day of clavulanate potassium in three divided doses)
Study: 3690939
Drug: Digoxin, 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin, 1.0 mg intravenously
Study: 25705798
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg yohimbine HCl
Study: 18496183
Drug: rFVIIa (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: rFVIIa (combined treatment group)
Study: 14712893
Drug: Antiplatelet agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet agents (specific agents not mentioned)
Study: 14712893
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of antiplatelet agents (specific agents not mentioned)
Study: 10925615
Drug: Single radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single radiation dose of 8 Gy